Mirador Capital Partners LP Has $2.82 Million Holdings in Iovance Biotherapeutics, Inc. $IOVA

Mirador Capital Partners LP grew its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 100.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,034,544 shares of the biotechnology company’s stock after buying an additional 519,519 shares during the period. Mirador Capital Partners LP’s holdings in Iovance Biotherapeutics were worth $2,824,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vontobel Holding Ltd. acquired a new position in shares of Iovance Biotherapeutics during the third quarter valued at about $26,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Iovance Biotherapeutics during the third quarter worth about $27,000. WealthTrust Axiom LLC increased its stake in Iovance Biotherapeutics by 80.0% during the second quarter. WealthTrust Axiom LLC now owns 18,000 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 8,000 shares during the period. Federated Hermes Inc. increased its stake in Iovance Biotherapeutics by 67.6% during the third quarter. Federated Hermes Inc. now owns 15,111 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 6,095 shares during the period. Finally, Wealthfront Advisers LLC acquired a new position in Iovance Biotherapeutics in the 3rd quarter valued at approximately $34,000. Institutional investors own 77.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on IOVA shares. Barclays raised their price objective on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 target price for the company in a research note on Tuesday, March 3rd. UBS Group raised their target price on Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a “neutral” rating in a research report on Thursday, March 5th. Wall Street Zen upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.88.

Iovance Biotherapeutics Trading Down 4.9%

NASDAQ IOVA opened at $3.51 on Friday. Iovance Biotherapeutics, Inc. has a 1-year low of $1.64 and a 1-year high of $5.63. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -3.13 and a beta of 0.69. The stock’s 50 day moving average is $3.32 and its two-hundred day moving average is $2.67.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The business had revenue of $86.77 million during the quarter, compared to analysts’ expectations of $81.61 million. Iovance Biotherapeutics had a negative return on equity of 54.54% and a negative net margin of 148.41%. On average, analysts predict that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.